Literature DB >> 1657913

Vaccinia virus encodes an active thymidylate kinase that complements a cdc8 mutant of Saccharomyces cerevisiae.

S J Hughes1, L H Johnston, A de Carlos, G L Smith.   

Abstract

A vaccinia virus open reading frame (ORF) previously predicted to encode thymidylate kinase (TmpK) is shown to encode an active enzyme. A copy of the ORF, generated by polymerase chain reaction, was cloned into an Escherichia coli inducible expression vector. Cell extracts of E. coli expressing the vaccinia gene contained high levels of TmpK activity, whereas extracts of cells without the TmpK gene did not. The vaccinia ORF expressed from a yeast vector complemented a Saccharomyces cerevisiae cdc8 mutant, demonstrating functional compatibility of the vaccinia virus and yeast TmpK enzymes. The gene is shown to be nonessential for the replication of vaccinia virus in cultured cells by the construction of a viable virus mutant that has the coding region of the TmpK gene interrupted by the Ecogpt gene. Synthesis of the vaccinia TmpK protein in infected cells was demonstrated by the use of a polyvalent rabbit antiserum raised against the purified TmpK enzyme expressed in E. coli to immunoprecipitate a 23-kDa early polypeptide from cells infected with wild type vaccinia but not from cells infected with the TmpK mutant. Plasmid vectors that allow the construction of recombinant viruses expressing foreign gene(s) from the nonessential TmpK locus are described.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657913

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence.

Authors:  W H Zhang; D Wilcock; G L Smith
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  The vaccinia virus superoxide dismutase-like protein (A45R) is a virion component that is nonessential for virus replication.

Authors:  F Almazán; D C Tscharke; G L Smith
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Diversity in the acute CD8 T cell response to vaccinia virus in humans.

Authors:  Lichen Jing; Tiana M Chong; Christopher L McClurkan; Jay Huang; Brian T Story; David M Koelle
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

4.  Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus.

Authors:  Kenneth L Johnson; Inna G Ovsyannikova; Benjamin J Madden; Gregory A Poland; David C Muddiman
Journal:  J Am Soc Mass Spectrom       Date:  2005-09-26       Impact factor: 3.109

5.  Genetic Confirmation that the H5 Protein Is Required for Vaccinia Virus DNA Replication.

Authors:  Kathleen A Boyle; Matthew D Greseth; Paula Traktman
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

Review 6.  Orthopoxvirus targets for the development of antiviral therapies.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Curr Drug Targets Infect Disord       Date:  2005-03

7.  Acidic residues in the membrane-proximal stalk region of vaccinia virus protein B5 are required for glycosaminoglycan-mediated disruption of the extracellular enveloped virus outer membrane.

Authors:  Kim L Roberts; Adrien Breiman; Gemma C Carter; Helen A Ewles; Michael Hollinshead; Mansun Law; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

8.  A mechanism for the inhibition of fever by a virus.

Authors:  A Alcamí; G L Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

9.  Human dUTP pyrophosphatase: cDNA sequence and potential biological importance of the enzyme.

Authors:  E M McIntosh; D D Ager; M H Gadsden; R H Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

10.  The African swine fever virus thymidine kinase gene is required for efficient replication in swine macrophages and for virulence in swine.

Authors:  D M Moore; L Zsak; J G Neilan; Z Lu; D L Rock
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.